ALK's nasal spray matches injections for anaphylaxis

Danish drugmaker ALK said its adrenaline nasal spray for treating severe allergic reactions produced a response comparable to an adrenaline injection, according to data presented at a European medical conference.

The company presented findings on its EURneffy nasal spray, designed for the emergency treatment of anaphylaxis, at the European Academy of Allergy and Clinical Immunology congress on Monday.

The data demonstrated that the nasal spray produces a pharmacological response comparable to an intramuscular adrenaline injection in patients with allergic rhinitis, the company said.

ALK also presented new data on its portfolio of under-the-tongue allergy immunotherapy tablets for children, including for respiratory allergies.

This included preliminary findings from its ALLIANCE clinical trial for a peanut allergy tablet, which the company said holds promise as a well-tolerated future treatment option.

The company announced positive interim results from the trial's first phase in December, advancing the tablet to Phase II testing.

“This year, we presented data on anaphylaxis, paediatric respiratory allergy, and food allergy, which is a testament to the dedication and high scientific standards in our company and our continuous focus on helping people living with allergy,” said Henriette Mersebach, Executive Vice President of Research & Development at ALK.